Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung

scientific article published on May 2006

Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1078-0432.CCR-05-1187
P698PubMed publication ID16675589
P5875ResearchGate publication ID7104615

P50authorSamuel D RabkinQ56473803
Robert L MartuzaQ88652671
P2093author name stringPetur G Nielsen
Susan Varghese
Wenzheng Wang
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectprostate cancerQ181257
oncolytic virusQ1560099
P304page(s)2919-2927
P577publication date2006-05-01
P1433published inClinical Cancer ResearchQ332253
P1476titleSystemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung
P478volume12

Reverse relations

cites work (P2860)
Q79915935A pox on your tumor
Q37287118Advances in oncolytic virus therapy for glioma
Q34612517Clinical experience with gene therapy for the treatment of prostate cancer.
Q36879211Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
Q39247534Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models
Q36142487Designing Herpes Viruses as Oncolytics
Q98177676Development of Spherical Nucleic Acids for Prostate Cancer Immunotherapy
Q37579001Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma
Q33713824Herpes simplex virus oncolytic therapy for pediatric malignancies
Q36890816NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Q35699072ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.
Q64104039Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells
Q35625500Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.
Q59793764Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins
Q39745964Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells
Q37615535Oncolytic virus therapy for prostate cancer
Q36109704Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.
Q50055098Potentiating prostate cancer immunotherapy with oncolytic viruses
Q35939421Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma
Q37882608Rethinking herpes simplex virus: the way to oncolytic agents

Search more.